Isolation of viable porcine islets by selective osmotic shock without enzymatic digestion. 2010

I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
Institute of Biomedical Sciences, University of Chile, Santiago, Chile. iatwater@med.uchile.cl

Islet transplantation is a potential cure for type 1 diabetes, but clinical results have been disappointing. Currently, islet isolation is by enzymatic digestion of the pancreas which has significant pitfalls: warm ischemia exposure, collagenase-induced damage to the islet mass and viability, poor reproducibility, high cost, a relatively low number of islets obtained per whole pancreas, and selection of islets for collagenase resistance rather than for glucose responsiveness. In the present study we performed a series of experiments in a porcine model to demonstrate the feasibility of a new isolation method based on selective osmotic shock (SOS) using very high glucose solutions, doubling or tripling physiological osmotic strength. The SOS method can be carried out at room temperature or in the cold eliminating warm ischemia time which damages the islets. The SOS method does not depend on the texture of the pancreas so all pancreases can be processed identically and the process can be fully automated. The SOS method isolates all the islets of the pancreas regardless of size and shape allowing a greater number of islets to be harvested. The SOS method avoids exposure to toxins in collagenase solutions, is inexpensive and selects for islets with high concentrations of Glut 2 transporters, representing the best glucose responding islets. The SOS method showed a comparable recovery of islets from young pig pancreas and the islets showed improved viability. We conclude that the selective osmotic shock (SOS) method of separating islets from the pancreatic tissue is superior to the collagenase method.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D009997 Osmotic Pressure The pressure required to prevent the passage of solvent through a semipermeable membrane that separates a pure solvent from a solution of the solvent and solute or that separates different concentrations of a solution. It is proportional to the osmolality of the solution. Osmotic Shock,Hypertonic Shock,Hypertonic Stress,Hypotonic Shock,Hypotonic Stress,Osmotic Stress,Hypertonic Shocks,Hypertonic Stresses,Hypotonic Shocks,Hypotonic Stresses,Osmotic Pressures,Osmotic Shocks,Osmotic Stresses,Pressure, Osmotic,Pressures, Osmotic,Shock, Hypertonic,Shock, Hypotonic,Shock, Osmotic,Shocks, Hypertonic,Shocks, Hypotonic,Shocks, Osmotic,Stress, Hypertonic,Stress, Hypotonic,Stress, Osmotic,Stresses, Hypertonic,Stresses, Hypotonic,Stresses, Osmotic
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
January 2024, Frontiers in veterinary science,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
January 1977, World journal of surgery,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
January 2017, Methods in molecular biology (Clifton, N.J.),
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
January 1999, Cell transplantation,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
May 2016, International endodontic journal,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
January 1960, Transactions of the Royal Society of Tropical Medicine and Hygiene,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
March 2018, Cell transplantation,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
April 1994, Transplantation proceedings,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
January 1977, World journal of surgery,
I Atwater, and M Guajardo, and P Caviedes, and S Jeffs, and D Parrau, and M Valencia, and C Romero, and C Arriagada, and E Caamaño, and A Salas, and F Olguin, and M Atlagich, and R Maas, and D Mears, and E Rojas
January 2012, Cell transplantation,
Copied contents to your clipboard!